Список литературы к Главе 16

188. Morra E., Nosari A., Montillo M. Infectious complications in chronic lymphocytic leukaemia // Hematol. Cell Ther. 1999. Vol. 41, N 4. P. 145–151.

189. Molteni A. et al. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes // Haematologica. 2005. Vol. 90, N 8. P. 1145–1147.

190. Novero A. et al. Ibrutinib for B cell malignancies // Exp. Hematol. Oncol. 2014. Vol. 3, N 1. P. 4.

191. Herman S.E. et al. Ibrutinib inhibits BCR and NF­κB signaling and reduces tumor proliferation in tissue­resident cells of patients with CLL // Blood. 2014. Vol. 123, N 21. P. 3286–3295.

192. Borge M. et al. Ibrutinib impairs the phagocytosis of rituximab­coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages // Haematologica. 2015. Vol. 100, N 4. P. e140–e142.

193. Weber A.N.R. et al. Bruton’s tyrosine kinase: an emerging key player in innate immunity // Front. Immunol. 2017. Vol. 8. P. 1454.

194. Byrd J.C. et al. Long­term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow­up of the RESONATE study // J. Clin. Oncol. 2017. Vol. 35, N 15. Suppl. P. 7510.

195. Byrd J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369, N 1. P. 32–42.

196. Byrd J.C. et al. Long­term follow­up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab // Blood. 2019. Vol. 133, N 19. P. 2031–2042.

197. Munir T. et al. Final analysis from RESONATE: Up to six years of follow­up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma // Am. J. Hematol. 2019. Vol. 94, N 12. P. 1353–1363.

198. Williams A.M. et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies // Leuk. Lymphoma. 2018. Vol. 59, N 3. P. 625–632.

199. O’Brien S. et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma // Clin. Lymphoma Myeloma Leuk. 2018. Vol. 18, N 10. P. 648–657.e15.

200. Dmitrieva E.A. et al. Infections in chronic lymphocytic leukemia patients treated with ibrutinib: incidence and predisposing factors // Clin. Oncohematol. 2019. Vol. 12. P. 438–448.

201. Burger J.A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia // N Engl. J. Med. 2015. Vol. 373, N 25. P. 2425–2437.

202. Barr P.M. et al. Sustained efficacy and detailed clinical follow­up of first­line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE­2 // Haematologica. 2018. Vol. 103, N 9. P. 1502–1510.

203. Burger J.A. et al. Safety and activity of ibrutinib plus rituximab for patients with high­risk chronic lymphocytic leukaemia: a single­arm, phase 2 study // Lancet Oncol. 2014. Vol. 15, N 10. P. 1090–1099.

204. Burger J.A. et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia // Blood. 2019. Vol. 133, N 10. P. 1011–1019.

205. Chanan­Khan A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double­blind, phase 3 study // Lancet Oncol. 2016. Vol. 17, N 2. P. 200–211.

206. Shanafelt T.D. et al. Ibrutinib­rituximab or chemoimmunotherapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2019. Vol. 381, N 5. P. 432–443.

207. Woyach J.A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL // N. Engl. J. Med. 2018. Vol. 379, N 26. P. 2517–2528.

208. Lee R. et al. Ibrutinib­associated Pneumocystis jirovecii pneumonia // Am. J. Hematol. 2017. Vol. 92, N 11. P. E646–E648.

209. Messina J.A. et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib // Open Forum Infect. Dis. 2017. Vol. 4, N 1. P. ofw261.

210. Baron M. et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis // Leuk. Lymphoma. 2017. Vol. 58, N 12. P. 2981–2982.

211. Arthurs B. et al. Invasive Aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia // Respir. Med. Case Rep. 2017. Vol. 21. P. 27–29.

212. Souers A.J. et al. ABT­199, a potent and selective BCL­2 inhibitor, achieves antitumor activity while sparing platelets // Nat. Med. 2013. Vol. 19, N 2. P. 202–208.

213. Deeks E.D. Venetoclax: first global approval // Drugs. 2016. Vol. 76, N 9. P. 979–987.

214. Deng R. et al. Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from the phase III MURANO study // Clin. Pharmacokinet. 2019. Vol. 58, N 12. P. 1621–1634.

215. Fischer K. et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions // N. Engl. J. Med. 2019. Vol. 380, N 23. P. 2225–2236.

216. Roberts A.W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 311-322.

217. Brumbaugh Paradis H., Alter D., Llerandi D. Venetoclax: management and care for patients with relapsed or refractory chronic lymphocytic leukemia // Clin. J. Oncol. Nurs. 2017. Vol. 21, N 5. P. 604–610.

218. Stilgenbauer S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open­label, phase 2 study // Lancet Oncol. 2016. Vol. 17, N 6. P. 768–778.

219. Jones J.A. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open­label, phase 2 trial // Lancet Oncol. 2018. Vol. 19, N 1. P. 65­75.

220. Coutre S. et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy // Blood. 2018. Vol. 131, N 15. P. 1704–1711.

221. Seymour J.F. et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study // Lancet Oncol. 2017. Vol. 18, N 2. P. 230–240.

222. Cramer P. et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2­BAG): primary endpoint analysis of a multicentre, open­label, phase 2 trial // Lancet Oncol. 2018. Vol. 19, N 9. P. 1215–1228.

223. Flinn I.W. et al. Phase 1b study of venetoclax­obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia // Blood. 2019. Vol. 133, N 26. P. 2765–2775.

224. Seymour J.F. et al. Venetoclax­rituximab in relapsed or refractory chronic lymphocytic leukemia // N. Engl. J. Med. 2018. Vol. 378, N 12. P. 1107–1120.

225. Byrd J.C. et al. Three­year follow­up of treatment­naive and previously treated patients with CLL and SLL receiving single­agent ibrutinib // Blood. 2015. Vol. 125, N 16. P. 2497–2506.

226. Hillmen P. et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study // J. Clin. Oncol. 2019. Vol. 37, N 30. P. 2722–2729.

227. Jain N. et al. Ibrutinib and venetoclax for first­line treatment of CLL // N. Engl. J. Med. 2019. Vol. 380, N 22. P. 2095–2103.

228. Reinwald M. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors) // Clin. Microbiol. Infect. 2018. Vol. 24, suppl. 2. P. S53–S70.

229. Leverson J.D. et al. Exploiting selective BCL­2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy // Sci. Transl. Med. 2015. Vol. 7, N 279. P. 279ra40.

230. Rogers K.A. et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia // Blood. 2018. Vol. 132, N 15. P. 1568–1572.

231. Gao R. et al. Diabetes mellitus is associated with inferior prognosis in patients with chronic lymphocytic leukemia: a propensity score­matched analysis // Cancer Res. Treat. 2020. Vol. 52, N 1. P. 189–206.

232. Casqueiro J., Casqueiro J., Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis // Indian J. Endocrinol. Metab. 2012. Vol. 16, suppl. 1. P. S27–S36.

233. Strati P. et al. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia // Haematologica. 2017. Vol. 102, N 1. P. e22–e25.

234. Curovic Rotbain E. et al. Mapping comorbidity in CLL: impact on prognostic factors, treatment patterns and causes of death // Blood. 2019. Vol. 134, suppl. 1. P. 4285–4285.